Published by Coherent Market Insights
Posted on September 15, 2021
4 min readLast updated: February 10, 2026
Add as preferred source on Google
Human reproductive technologies assist parents who are having troubles in pregnancies, and infertility issues. These technologies include Assisted Reproductive Technology (ART), prognostics, contraception, and same-sex procreation. ART aids in the treatment of low fertility or infertility using artificial insemination, artificial reproduction, cloning, cytoplasmic transfer, fertility medication, hormone treatment, and others.
Increasing prevalence of maternal mortality is expected to propel growth of the global human reproductive technologies market over the forecast period. For instance, according to Maternal Mortality: 1990 to 2015 Estimates by WHO, UNICEF, UNFPA, World Bank Group and the United Nations Population Division, Sub-Saharan Africa recorded the highest ratio or maternal mortality, at 555 per 100, 000 live births, from 1990 to 2015. Moreover, the United Nations is focused on achieving the Sustainable Development Goals 2015 – 2030 global maternal mortality ratio target of less than 70 per 100 000 live births.
Request Sample Copy + related graphs of the report@ https://www.coherentmarketinsights.com/insight/request-sample/3921
Moreover, decreasing birth rate is also expected to aid in growth of the market. For instance, according to National Vital Statistics System, the provisional number of births for the U.S. in 2018 was 3,788,235, registering a decrease of 2% from 2017 and the lowest number of births in 32 years.
North America held dominant position in the global human reproductive technologies market in 2019, accounting for 46.1% share in terms of value, followed by Europe and Asia Pacific, respectively.Increasing rate of literacy is expected to offer lucrative growth opportunities for players in the global human reproductive technologies market. For instance, according to United Nations Children’s Fund, globally, the youth literacy rate increased from 83% to 91% during 1985-2018.
Moreover, R&D in male birth control pill is also expected to aid in growth of the market. For instance, in March 2018, researchers from the University of Washington presented positive results from a small clinical trial of 100 men for a male birth control pill that inhibits testosterone production.
The global human reproductive technologies market was valued at US$ 28,426.7 Mn in 2019 and is forecast to reach a value of US$ 34,228.3 Mn by 2027 at a CAGR of 2.4% between 2020 and 2027.
Major players operating in the global human reproductive technologies include, Abbott Laboratories, Evofem Biosciences, Inc., Actavis Generics (Teva Pharmaceutical Industries Ltd.), Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Uniprix, Gavis Pharmaceuticals (Lupin Limited), Sandoz International GmbH, Aurobindo Pharma Limited, HRA Pharma, SA, Mankind Pharma, Cryos USA, Merck & Co, Bayer HealthCare AG, Church & Dwight, Co. Inc., Allergan, Pfizer, Inc., Agile Therapeutics Inc., BioSante Pharmaceuticals Inc., Mayer Laboratories, Inc., Pantarhei Bioscience B.V., Cook Medical, Inc., Ferring Pharmaceuticals, Johnson & Johnson, Daré Bioscience, Inc., and Merck Serono.
Major players in the market are focused on approval and launch of new products to expand their product portfolio. For instance, in May 2020, Evofem Biosciences, Inc. received the U.S. Food and Drug Administration (FDA) approval for Phexxi (lactic acid, citric acid and potassium bitartrate) vaginal gel used to prevent pregnancy in females of reproductive potential for use as an on-demand method of contraception.
Request Here For PDF Brochure:
https://www.coherentmarketinsights.com/insight/request-pdf/3921
Major players in the market are also focused on adopting partnership strategies to expand their product portfolio. For instance, in May 2020, Daré Bioscience, Inc., a developer of women’s health solutions partnered with Health Decisions, Inc., a full-service contract research organization (CRO) specializing in women’s health clinical research and diagnostic development, under which Health Decisions will exclusively provide CRO services within the U.S. to support R&D of Daré’s pipeline of contraception, fertility, and gynecological disorders products.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
The post Human Reproductive Technologies Market Set to Encounter Paramount Growth with Myriad Advances appeared first on Gatorledger.
The increasing prevalence of maternal mortality and a decreasing birth rate are expected to propel the growth of the global human reproductive technologies market.
The global human reproductive technologies market was valued at US$ 28,426.7 million in 2019.
North America held a dominant position in the global human reproductive technologies market in 2019, accounting for 46.1% share in terms of value.
Major players operating in the market include Abbott Laboratories, Evofem Biosciences, Inc., and Sun Pharmaceutical Industries, among others.
The market is forecast to reach a value of US$ 34,228.3 million by 2027, growing at a CAGR of 2.4% between 2020 and 2027.
Explore more articles in the Research Reports category
